These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33516660)

  • 1. Cancer of Unknown Primary in the Molecular Era.
    Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
    Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
    Rassy E; Pavlidis N
    Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
    JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer of unknown primary.
    Lee MS; Sanoff HK
    BMJ; 2020 Dec; 371():m4050. PubMed ID: 33288500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
    Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
    Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
    Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
    J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
    Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
    Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
    Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
    Greco FA
    Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
    Pentheroudakis G; Greco FA; Pavlidis N
    Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
    Yang JW; Choi YL
    Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.
    Wang X; Beharry A; Sheffield BS; Cheema PK
    Oncologist; 2023 Jun; 28(6):474-478. PubMed ID: 36933203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer of unknown primary site: evolving understanding and management of patients.
    Greco FA
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):518-24. PubMed ID: 23073050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification].
    Morawietz L; Floore A; Stork-Sloots L; Folprecht G; Buettner R; Rieger A; Dietel M; Huebner G
    Pathologe; 2009 Dec; 30 Suppl 2():168-72. PubMed ID: 19756615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
    Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
    Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
    Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.